ALK and non-small cell lung carcinoma: ATP-competitive ALK/Met/ROS1 tyrosine kinase inhibitors (TKIs), such as crizotinib, have transformed the treatment of patients with non-small cell lung carcinoma (NSCLC) harboring ALK translocations10 and demonstrated differential activity in pre-clinical models of ALK-driven neuroblastoma11.